Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01066897 · ClinicalTrials.gov registry record · Phase 4

Imaging the Nucleus Accumbens in Major Depressed Patients 'Treated With Pramipexole

A Phase 4 study, sponsored by Stanford University.

Terminated
Registry status
Phase 4
Development phase
16
Enrollment target

NCT01066897: Clinical Trial Phase 4 study, sponsored by Stanford University.

NCT01066897 is a Phase 4 study that was terminated before completion, run by Stanford University. The registered enrollment target is 16 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT01066897, a Phase 4 study, was terminated before completion, sponsored by Stanford University.

TERMINATED
Registry status
Phase 4
Development phase
16 participants
Enrollment target

Study Summary

We hope to learn how a brain circuit that is important to the understanding of depression, anhedonia and positive affect responds to a novel pharmaceutical treatment for depression and related symptoms. Adults who have a diagnosis of major depression and are not completely responsive to antidepressant medication will be sought out for participation; as will an equal number of adults not suffering from the disorder. Those suffering from depression will be given pramipexole, an investigational medication for eight weeks during which information will be collected about mood, cognition, and brain function. Adults not suffering from depression will also be evaluated with these measures.

Interventions

  • DRUG Pramipexole

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2010-02
Est. Completion 2013-02
Phase Phase 4
Stanford University

1,744 total trials

Why NCT01066897 stopped before completion

NCT01066897 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower).

The record links to 0 conditions, and to 1 intervention - of which Pramipexole is the first listed.

NCT01066897 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01066897 about?

NCT01066897 is a clinical study titled "Imaging the Nucleus Accumbens in Major Depressed Patients 'Treated With Pramipexole". We hope to learn how a brain circuit that is important to the understanding of depression, anhedonia and positive affect responds to a novel pharmaceutical treatment for depression and related symptoms. Adults who have a diagnosis of major depression and are not completely responsive to antidepressa...

What is the current status of trial NCT01066897?

This trial is currently terminated. It is a Phase 4 study. The enrollment target is 16 participants. The study started on 2010-02. Estimated completion is 2013-02.

What interventions are being tested in trial NCT01066897?

The interventions under investigation include: Pramipexole (DRUG).

Who is sponsoring clinical trial NCT01066897?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01066897's enrollment target sits among peer trials

16 1869th of 2000 higher than 121 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02422641 · 16 participants · Phase 2

    Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

  • NCT02851758 · 16 participants · NA

    Transplantation of Autologously Derived Mitochondria Following Ischemia

  • NCT03291028 · 16 participants

    Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma

  • NCT03425526 · 16 participants · Phase 1

    Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01066897, the US trial registry maintained by the National Library of Medicine. NCT01066897 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.